Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib

Vismodegib is a first-in-class agent targeting the hedgehog signaling pathway for treatment of patients with locally advanced basal cell carcinoma (BCC) and metastatic BCC. There have been concerns about the development of squamous cell carcinoma (SCC) in patients treated with this drug.

http://ift.tt/2uYIenn